BioInvent International AB announces third customer for n-CoDeR (TM) antibody library

BioInvent International AB announces third customer for n-CoDeR antibody library Lund, Sweden: BioInvent International AB, the privately held Swedish antibody company, today announces that Oxford GlycoSciences Plc (LSE: OGS; NASDAQ: OGSI) ("OGS") has become the third customer for its n-CoDeR antibody library. OGS is one of the world's leading proteomics companies, specialising in the comprehensive study of proteins. Under the terms of the contract BioInvent will use n-CoDeR, its unique proprietary human antibody gene library, to isolate and provide human antibody-based research reagents in a specific, but undisclosed, area for OGS. This is the third deal for BioInvent this year using the Group's antibody gene library. The two previous deals were with Novo Nordisk and the vaccine unit of GlaxoSmithKline. Svein Mathisen, Chief Executive Officer of BioInvent, commenting on this most recent deal, said: "To have signed a deal with one of the UK's leading biotechnology companies is obviously extremely exciting for BioInvent. The fact that this is the third deal of its kind for us in as many months shows that the global lifescience industry is beginning to realise the significance and power of our technology to generate unique human antibodies." For further information, please contact: BioInvent Tel: +46 (0)46 286 85 50 Svein Mathisen, Chief Executive Officer Göran Conradson, VP Business Development Buchanan Communications Tel: +44 (0)20 7466 5000 Nicola How / Edward Cowdery Notes to Editors: BioInvent International AB is a privately held biotechnology company devoted to providing state-of-the-art antibody technology to the pharmaceutical and biotech industry. A cornerstone is its proprietary human antibody gene library, n-CoDeR(TM). This is a collection of more than ten billion functional antibody genes which are ready to be screened against desired antigens. n-CoDeR(TM) has been used successfully for the isolation of antibody fragments with specificity for a number of antigens, including peptides, proteins and carbohydrates. BioInvent offers biotechnology and pharmaceutical companies access to n-CoDeR(TM) through collaborative research and development programs. BioInvent's capabilities in large-scale contract manufacturing of protein based drugs through a state-of-the-art cGMP-certified facility further underpins its competitiveness on the antibody arena. BioInvent has been supplying monoclonal antibodies, fusion proteins and other recombinant proteins to the world's leading pharmaceutical and biotechnology companies for therapeutic use since 1988. These antibodies and proteins are used in all phases of clinical trials in both the US and across Europe. The cGMP-certified production facility is designed to meet FDA and EU regulations from early clinical development to commercial scale-up, with multi-kilogram annual capacity. BioInvent is headquartered in Lund, Sweden, employing a total 100 people. For further information visit our website www.bioinvent.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00770/wkr0001.doc http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00770/wkr0002.pdf